These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3342417)

  • 1. Guidelines for the use of Intron A (interferon alfa-2b) in clinical oncology: lessons from the laboratory.
    Smyth JF
    Cancer Treat Rev; 1988 Jan; 15 Suppl A():3-6. PubMed ID: 3342417
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical use of interferon alfa-2b (intron-A): the Manchester experience.
    Scarffe JH; Wagstaff J; Crowther D
    Ann Ist Super Sanita; 1987; 23(4):777-8. PubMed ID: 3452285
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol.
    Mandelli F; Tribalto M; Avvisati G; Cantonetti M; Petrucci MT; Boccadoro M; Pileri A; Marmont F; Resegotti L; Lauta V
    Cancer Treat Rev; 1988 Jan; 15 Suppl A():43-8. PubMed ID: 3277709
    [No Abstract]   [Full Text] [Related]  

  • 4. INTRON A (interferon alfa-2b): clinical overview.
    Spiegel RJ
    Cancer Treat Rev; 1985 Dec; 12 Suppl B():5-16. PubMed ID: 3914355
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Ph'-positive chronic myelogenous leukemia (CML) with recombinant interferon alfa-2b (Intron A).
    Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inveradi D; Bernasconi P; Mancini M; Grignani F; Bernasconi C
    Cancer Treat Rev; 1988 Jan; 15 Suppl A():21-6. PubMed ID: 3277708
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of metastatic malignant melanoma with recombinant interferon alfa-2b.
    Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Falcoff E; Schwab D; Lerminier M; Pouillart P
    Invest New Drugs; 1987; 5 Suppl():S61-3. PubMed ID: 3597003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for the integration of Intron A (interferon alfa-2b) into the treatment of hematological malignancies. Proceedings of a satellite symposium at the Third International Conference on Malignant Lymphoma. Lugano June 1987.
    Cancer Treat Rev; 1988 Jan; 15 Suppl A():1-65. PubMed ID: 3342416
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b.
    Niederle N; Kloke O; May D; Becher R; Osieka R; Schmidt CG
    Invest New Drugs; 1987; 5 Suppl():S19-25. PubMed ID: 3474219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferons in the treatment of multiple myeloma.
    Cooper MR
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):13-20. PubMed ID: 3764441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alfa-2b in the treatment of chronic granulocytic leukemia.
    Bergsagel DE; Haas RH; Messner HA
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):29-34. PubMed ID: 3464099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alfa for macular degeneration.
    Williford SL; King T
    Ann Pharmacother; 1996 Jun; 30(6):678-9. PubMed ID: 8792957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A).
    Spiegel RJ; Spicehandler JR; Jacobs SL; Oden EM
    Am J Med; 1986 Feb; 80(2):223-8. PubMed ID: 3484902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy.
    Vonderheid EC; Thompson R; Smiles KA; Lattanand A
    Arch Dermatol; 1987 Jun; 123(6):757-63. PubMed ID: 3579357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of preclinical and clinical studies of interferon alfa-2b in combination with cytotoxic drugs.
    Welander CE
    Invest New Drugs; 1987; 5 Suppl():S47-59. PubMed ID: 3298133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antitumor effect of the Soviet recombinant alpha2-interferon (reaferon) under experimental conditions].
    Lavrukhina LA; Posevaia TA; Barinskiĭ IF; Ershov FI
    Vopr Virusol; 1989; 34(3):312-5. PubMed ID: 2477953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of recombinant human interferon-alpha A/D on the growth of experimental tumors in mice].
    Ootsu K; Kozai Y; Houkan T; Gotoh K; Matsutani E
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2502-8. PubMed ID: 3304169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferons in the treatment of multiple myeloma.
    Cooper MR; Welander CE
    Cancer; 1987 Feb; 59(3 Suppl):594-600. PubMed ID: 3802025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic options in advanced cutaneous T cell lymphomas: a role for interferon alfa-2a (Roferon-A).
    Bunn PA; Foon KA
    Semin Oncol; 1985 Dec; 12(4 Suppl 5):18-24. PubMed ID: 3878594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intron A (interferon alfa-2b): clinical overview and future directions.
    Spiegel RJ
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):89-101. PubMed ID: 3532338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A).
    Volberding PA; Mitsuyasu RT; Golando JP; Spiegel RJ
    Cancer; 1987 Feb; 59(3 Suppl):620-5. PubMed ID: 3492260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.